IMCIO2026
Paris, France October 26-28, 2026
Early Bird Registration February 06, 2026
About Conference
Inscitech Meet On Cancer and Immuno-Oncology
Inscitech
Meet on Cancer and Immuno-Oncology (IMCIO2026) is an international
conference dedicated to showcasing the latest advancements, innovations, and
research in the dynamic fields of Cancer and Immuno-Oncology. Scheduled to take
place from October 26-28, 2026 in the vibrant city of Paris,
France. IMCIO2026 brings together leading academics, researchers,
doctors, and industry professionals from around the globe.
Organized by InSciTech Summits, this three-day event provides a
multidisciplinary platform for exchanging cutting-edge ideas, discussing
real-world applications, and fostering collaborations across academia and
industry. The program will feature plenary and keynote talks, technical sessions,
interactive panels, and networking opportunities designed to inspire innovation
and promote technological advancement.
Market Analysis- IMCIO2026
The Cancer
and Immuno-Oncology market is valued at approximately USD 109.61 billion and is
projected to reach USD 155.07 billion by 2030, growing at a CAGR of 6.14 %.
Sub-segments such as cancer sequencing and oncology services are also
witnessing strong growth, with cancer sequencing expected to rise from USD 109.61billion
in 2025 to USD 155.07 billion by 2034.
Best Regards
Kyathi Lara
Event Manager
Important Dates
Conference Updates
- Conference Dates October 26-28, 2026
- Early Bird Registration February 06, 2026
- Abstract Submission Deadline February 06, 2026
- Conference Venue Paris, France
Collaborations and Event Updates
Scientific Sessions
- Genitourinary Cancers
- Cell & Gene Therapy in Oncology
- Radiotheranostics & Targeted Radiopharma
- Liquid Biopsy & MRD
- AI, Imaging & Decision Support
- Real-World Data & Outcomes
- Treatment Resistance & Sequencing
- Nursing & Allied Oncology Practice
- Breast Oncology
- Melanoma & Skin Cancers
- Pediatric & AYA Oncology
- Cancer Vaccines & Oncolytic Platforms
- Radiation & Combined-Modality Therapy
- Education, Patient Advocacy & Equity
- Immuno-Oncology
- Hematologic Malignancies
- Antibody-Drug Conjugates (ADCs)
- Precision Oncology & Biomarkers
- Early Detection & Screening
- Trials Design & Innovation
- Peri-/Neoadjuvant Strategies
- Supportive Care & Survivorship
- Health Economics, Access & Policy
- Lung & Thoracic Oncology
- Head & Neck / Neuro-Oncology
- Microbiome, Metabolism & Tumor Microenvironment
- Imaging-Guided Therapy & Response Assessment
- Quality Improvement & Safety
